Boehringer Ingelheim has formed an alliance with OSE Immunotherapeutics to develop a SIRP-alpha antagonist compound to treat advanced solid tumours.

Under the collaboration and licence agreement, the companies will work together on the monoclonal antibody OSE-172 that is currently in late preclinical development for multiple cancers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SIRP-alpha is a receptor expressed by myeloid lineage cells and its inhibition is expected to prevent the binding of CD47 ligand to the receptor, causing cellular inhibitory effects.

Boehringer believes that OSE-172 can improve T cell activity and anti-tumour immunity.

Boehringer Ingelheim cancer immunology and immune modulation research global head Jonathon Sedgwick said: “A key area of focus is the identification of drugs that target myeloid cell immune regulatory receptors of which SIRP-alpha is a leading example.

“We are dedicated to developing ground-breaking, first-in-class therapies that can transform the lives of patients and help win the fight against cancer.”

“We are dedicated to developing ground-breaking, first-in-class therapies that can transform the lives of patients and help win the fight against cancer.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Boeringher will acquire the global rights to develop, register and commercialise the compound. OSE Immunotherapeutics will obtain €15m upfront and up to €1m in potential short-term milestones after the launch of a Phase I clinical trial.

The company could receive more than €1.1bn upon reaching pre-specified development, commercialisation and sales milestones, plus royalties on worldwide net sales.

OSE Immunotherapeutics CEO Dominique Costantini said: “This partnership with Boehringer Ingelheim is a real recognition of the value of our innovative approach to treating cancer and will create an exciting new alliance to fuel the Phase I development of OSE-172.

“Boehringer Ingelheim’s expertise and insights will be invaluable as we step up the clinical development and work to commercialise this new treatment paradigm.”